Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email email@example.com.
Check back regularly for news, coverage, and announcements about MAVA.
Surface Oncology has secured $35 million in Series A funding.
Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding.
Biotech accelerator Cydan Development Inc. announced Wednesday $25 million in Series A funding to launch Vtesse Inc., which will focus on developing treatments for lysosomal storage diseases, a collection of rare, typically fatal disorders usually affecting children.
NanoLumens, the world's leader for visualization solutions in any size, shape or curvature, today announced it has secured $13.3-million in new financing from an offering of debt and securities.
ThermiAesthetics, a fast growing, privately held aesthetic technology company, announced today that it has secured $9,000,000 of debt financing from Cypress Growth Capital and Silicon Valley Bank.
McLean-based BigTeams announced Monday morning both a Series B funding round of $5 million and the acquisition of software provider Schedule Star from Gannett.
Baltimore-based OpiaTalk has raised $500,000 to put toward making its e-commerce widget available on mobile devices.
Arlington-based Endgame, the maker of security and intelligence software for large enterprises, has raised $30 million from a slate of New York and Silicon Valley investors as the company looks to push further into the private sector.
A District-based start-up that uses artificial intelligence to predict the outcome of legislation has received $7 million in funding, including investments from the Singapore sovereign wealth fund and from the Winklevoss twins, made famous from their lawsuits against Facebook.
ADMA Biologics, Inc. (Nasdaq:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases, today announced that it has received a $5 million tranche from Hercules Technology Growth Capital, Inc. (NYSE:HTGC), the leading specialty finance company focused on providing senior secured loans to venture capital-backed companies in technology-related markets.